KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Liabilities and Shareholders Equity: 2009-2024

Historic Liabilities and Shareholders Equity for Ionis Pharmaceuticals (IONS) over the last 16 years, with Dec 2024 value amounting to $3.0 billion.

  • Ionis Pharmaceuticals' Liabilities and Shareholders Equity fell 1.56% to $3.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $11.8 billion, marking a year-over-year increase of 2.68%. This contributed to the annual value of $3.0 billion for FY2024, which is 0.45% up from last year.
  • Ionis Pharmaceuticals' Liabilities and Shareholders Equity amounted to $3.0 billion in FY2024, which was up 0.45% from $3.0 billion recorded in FY2023.
  • Ionis Pharmaceuticals' Liabilities and Shareholders Equity's 5-year high stood at $3.0 billion during FY2024, with a 5-year trough of $2.4 billion in FY2020.
  • Its 3-year average for Liabilities and Shareholders Equity is $2.8 billion, with a median of $3.0 billion in 2023.
  • In the last 5 years, Ionis Pharmaceuticals' Liabilities and Shareholders Equity declined by 26.08% in 2020 and then grew by 18.00% in 2023.
  • Yearly analysis of 5 years shows Ionis Pharmaceuticals' Liabilities and Shareholders Equity stood at $2.4 billion in 2020, then rose by 9.29% to $2.6 billion in 2021, then decreased by 2.98% to $2.5 billion in 2022, then rose by 18.00% to $3.0 billion in 2023, then rose by 0.45% to $3.0 billion in 2024.